$24.30
1.25% today
Nasdaq, Aug 22, 10:17 pm CET
ISIN
US47103J1051
Symbol
JANX

Janux Therapeutics Inc Stock price

$24.30
-2.08 7.88% 1M
-9.28 27.64% 6M
-29.24 54.61% YTD
-19.90 45.02% 1Y
+10.05 70.53% 3Y
-0.85 3.38% 5Y
-0.85 3.38% 10Y
-0.85 3.38% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.30 1.25%
ISIN
US47103J1051
Symbol
JANX
Industry

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$446.2m
Net debt
positive
Cash
$996.0m
Shares outstanding
59.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3,277.9 | 3,534.9
EV/Sales
1,014.2 | 1,093.7
EV/FCF
negative
P/B
1.5
Financial Health
Equity Ratio
96.3%
Return on Equity
-6.7%
ROCE
-14.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$440.0k | $408.0k
EBITDA
$-142.8m | $-148.1m
EBIT
$-144.9m | $-162.4m
Net Income
$-105.6m | $-123.9m
Free Cash Flow
$-60.7m
Growth (TTM | estimate)
Revenue
-97.1% | -96.2%
EBITDA
-123.6% | -53.0%
EBIT
-119.7% | -64.3%
Net Income
-139.8% | -79.6%
Free Cash Flow
-27.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-32,527.8% | -36,290.8%
EBIT
-33,002.1%
Net
-24,064.0% | -30,366.5%
Free Cash Flow
-13,827.8%
More
EPS
$-1.7
FCF per Share
$-1.0
Short interest
21.3%
Employees
103
Rev per Employee
$100.0k
Show more

Is Janux Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Janux Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Janux Therapeutics Inc forecast:

19x Buy
90%
2x Hold
10%

Analyst Opinions

21 Analysts have issued a Janux Therapeutics Inc forecast:

Buy
90%
Hold
10%

Financial data from Janux Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.44 0.44
97% 97%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 46 46
65% 65%
10,495%
- Research and Development Expense 99 99
87% 87%
22,532%
-143 -143
124% 124%
-32,455%
- Depreciation and Amortization 2.08 2.08
0% 0%
473%
EBIT (Operating Income) EBIT -145 -145
120% 120%
-32,927%
Net Profit -106 -106
140% 140%
-24,009%

In millions USD.

Don't miss a Thing! We will send you all news about Janux Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Janux Therapeutics Inc Stock News

Positive
The Motley Fool
15 days ago
Janux Therapeutics (JANX -6.49%), a clinical-stage biotechnology company focused on developing next-generation immunotherapies, reported second quarter results on August 7, 2025. The main headline: the company posted a net loss as it continued to invest heavily in its pipeline, with GAAP revenue missing analyst forecasts by $0.25 million.
Neutral
Business Wire
15 days ago
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today reported financial re...
Neutral
Business Wire
17 days ago
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced the dosing ...
More Janux Therapeutics Inc News

Company Profile

Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.

Head office United States
CEO David Campbell
Employees 103
Founded 2017
Website www.januxrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today